



PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/844,544
				Filing Date	April 27, 2001
				First Named Inventor	Defu Zeng
				Art Unit	1644
				Examiner Name	Marianne Nmn Dibrino
Sheet	1	Of	6	Attorney Docket Number 31580-702.201	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/MD/	1.	US 2001/0051156	12/13/2001	Zeng et al.	
	2.	US 2003/0206914	11/06/2003	Porcelli et al.	
	3.	US 2004/0127429	07/01/2004	Tsuji et al.	
	4.	US 2004/0171527	09/02/2004	Ilan et al.	
	5.	US 2005/0159365	07/21/2005	Serizawa et al.	
	6.	US 4,885,285	12/05/1989	Baschang et al.	
	7.	US 5,705,187	01/06/1998	Unger	
	8.	US 5,851,543	12/22/1998	Korb et al.	
	9.	US 5,945,409	08/31/1999	Crandall	
	10.	US 6,531,453	03/11/2003	Taniguchi et al.	
	11.	US 6,747,010	06/08/2004	Taniguchi et al.	
/MD/	12.	US 7,063,844	06/20/2006	Porcelli et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>1</sup> - Number <sup>1</sup> - Kind Code <sup>1</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
/MD/	13.	DE 198 41 794 A1 (in German with English Abstract)	03/16/2000	Beiersdorf AG		
/MD/	14.	EP 0751780 B1	09/03/2003	Porcelli et al.		
/MD/	15.	EP 0988860 A1	03/29/2000	Kirin Beer Kabushiki Kaisha		
/MD/	16.	JP 08116971A (in Japanese with English abstract)	05/14/1996	Kanebo LTD		
/MD/	17.	JP 11-302155A2 (in	11/02/1999	La Shinshia KK		

Examiner Signature	/Marianne Dibrino/	Date Considered	01/28/2008
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/844,544
				Filing Date	April 27, 2001
				First Named Inventor	Defu Zeng
				Art Unit	1644
				Examiner Name	Marianne Nmn Dibrino
Sheet	2	Of	6	Attorney Docket Number	31580-702.201

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>1</sup> - Number <sup>2</sup> - Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
/MD/		Japanese with English abstract)	<i>(Continued from page 1)</i>			
	18.	JP 2000-264825A2 (in Japanese with English abstract)				
	19.	JP 2000-264829A2 (in Japanese with English abstract)	09/26/2000	Fanci Corp		
	20.	JP 5-331049 (in Japanese with English abstract)	12/14/1993	Pola Chem Ind Inc.		
	21.	JP H8-116971A (in Japanese with English translation)	05/14/1996	Hara et al.		
	22.	WO 99/29293 A1	06/17/1999	DSM N.V.		
	23.	WO 02/051986 A2	07/04/2002	Ilan et al.		
	24.	WO 02/051986 A3	09/12/2002	Ilan et al. <i>(Abstract only)</i>		
	25.	WO 2004/028475 A2	04/08/2004	Jiang et al.		
/MD/	26.	WO 2004/028475 A3	01/05/2006	Jiang et al.		

4/8/09

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/MD/	27.	AMOURA, et al. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum. 2000; 43(1):76-84.	

Examiner Signature	/Marianne Dibrino/	Date Considered	01/28/2008
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-736-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	09/844,544	
				Filing Date	April 27, 2001	
				First Named Inventor	Defu Zeng	
				Art Unit	1644	
				Examiner Name	Marianne Nmn Dibrino	
Sheet	3	Of	6	Attorney Docket Number		31580-702.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/MD/	28.	APOSTOLOU, et al. Murine natural killer T(NKT) cells [correction of natural killer cells] contribute to the granulomatous reaction caused by mycobacterial cell walls. Proc Natl Acad Sci USA. 1999; 96(9): 5141-6.	
	29.	BONISH, et al. Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J Immunol. 2000; 165(7): 4076-85.	
	30.	BRIKEN, et al. Diversification of CD1 proteins: sampling the lipid content of different cellular compartments. Semin Immunol. 2000 Dec;12(6):517-25.	
	31.	CHANG, et al. The synthesis and biological characterization of a ceramide library. J Am Chem Soc. 2002 Mar 6;124(9):1856-7.	
	32.	DiSEPIO, et al. Novel approaches for the treatment of psoriasis. Drug Discov Today. 1999 May;4(5):222-231.	
	33.	EL-GABALAWY, et al. Why do we not have a cure for rheumatoid arthritis? Arthritis Res. 2002;4 Suppl 3:S297-301.	
	34.	ELKHAL, et al. CD1d restricted natural killer T cells are not required for allergic skin inflammation. J Allergy Clin Immunol. 2006; 118(6): 1363-8.	
	35.	ERIEBACHER, et al. Ovarian insufficiency and early pregnancy loss induced by activation of the innate immune system. J Clin Invest. 2004 Jul;114(1):39-48.	
	36.	FAYYAZI, et al. T lymphocytes and altered keratinocytes express interferon-gamma and interleukin 6 in lichen planus. Arch Dermatol Res. 1999; 291(9): 485-80.	
/MD/	37.	FILION, et al. Anti-inflammatory activity of cationic lipids. Br J Pharmacol. 1997 Oct;122(3):551-7.	

Examiner Signature	/Marianne Dibrino/	Date Considered	01/28/2008
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/844,544
				Filing Date	April 27, 2001
				First Named Inventor	Defu Zeng
				Art Unit	1644
				Examiner Name	Marianne Nmn Dibrino
Sheet	4	Of	6	Attorney Docket Number	31580-702.201

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
/MD/	38.	FORESTIER, et al. Expansion and hyperactivity of CD1d-restricted NKT cells during the progression of systemic lupus erythematosus in (New Zealand Black x New Zealand White)F1 mice. J Immunol. 2005; 175(2): 763-70.		
	39.	HAMANAKA, S. et al. 1995. A trial of galactosylceramide containing cream to the patients with atopic skin and xerosis. <i>Skin Research</i> . 37(5): 619-625. (in Japanese with English abstract)		
	40.	ITO, et al. Involvement of decidual Valpha14 NKT cells in abortion. Proc Natl Acad Sci USA. 2000; 97(2): 740-4.		
	41.	KANEKO, et al. Augmentation of Valpha14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J Exp Med. 2000; 191(1): 105-14.		
	42.	KAWANO, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science. 1997 Nov 28;278(5343):1626-9.		
	43.	KOBAYASHI, et al. Enhancing effects of alpha-,beta-monoglycosylceramides on natural killer cell activity. Bioorg Med Chem. 1996; 4(4): 615-9.		
	44.	KRONENBERG, et al. Right on target: novel approaches for the direct visualization of CD1-specific T cell responses. Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):2950-2.		
	45.	KUPPER, T. Immune and inflammatory processes in cutaneous tissues. Mechanisms and speculations. J Clin Invest. 1990 Dec;86(6):1783-9.		
	46.	MADDISON, P. Autoantibodies in SLE. Disease associations. Adv Exp Med Biol. 1999;455:141-5.		
/MD/	47.	MAGNAN, et al. Relationships between natural T cells, atopy, IgE levels, and IL-4 production. Allergy. 2000; 55(3): 286-90.		

Examiner Signature	/Marianne Dibrino/	Date Considered	01/28/2008
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	09/844,544	
				Filing Date	April 27, 2001	
				First Named Inventor	Defu Zeng	
				Art Unit	1644	
				Examiner Name	Marianne Nmn Dibrino	
Sheet	5	Of	6	Attorney Docket Number		31580-702.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/MD/	48.	MARUYAMA, et al. Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). Biochim Biophys Acta. 1992 Sep 22;1128(1):44-9.	
	49.	MEMPEL, et al. Comparison of the T cell patterns in leprosy and cutaneous sarcoid granulomas. Presence of Valpha24-invariant natural killer T cells in T-cell-reactive leprosy together with a highly biased T cell receptor Valpha repertoire. Am J Pathol. 2000 Aug;157(2):509-23.	
	50.	NAIDENKO, et al. Binding and antigen presentation of ceramide-containing glycolipids by soluble mouse and human CD1d molecules. J Exp Med. 1999 Oct 18;190(8):1069-80. 1079	
	51.	NAUMOV, et al. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13838-43.	
	52.	NICKOLOFF, et al. Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J Dermatol Sci. 2000 Dec;24(3):212-25.	
	53.	NICKOLOFF, et al. Response of murine and normal human skin to injection of allogeneic blood-derived psoriatic immunocytes: detection of T cells expressing receptors typically present on natural killer cells, including CD94, CD158, and CD161. Arch Dermatol. 1999 May;135(5):546-52.	
	54.	NIEDA, et al. Activation of human Valpha24NKT cells by alpha-glycosylceramide in a CD1d-restricted and Valpha24TCR-mediated manner. Hum Immunol. 1999 Jan;60(1):10-19.	
	55.	PARK, et al. Inhibitory activity of a ceramide library on interleukin-4 production from activated T cells. Bioorg Med Chem. 2005 Apr 1;13(7):2589-95.	
/MD/	56.	PELTIER, M. Immunology of term and preterm labor. Reprod Biol Endocrinol. 2003 Dec 2;1:122 (pages 1-11).	

Examiner Signature	/Marianne Dibrino/	Date Considered	01/28/2008
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	09/844,544	
				Filing Date	April 27, 2001	
				First Named Inventor	Defu Zeng	
				Art Unit	1644	
				Examiner Name	Marianne Nmn Dibrino	
Sheet	6	Of	6	Attorney Docket Number		31580-702.201

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
/MD/	57.	SHI, et al. Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6777-82.		
	58.	SINGH, et al. T cell determinants from autoantibodies to DNA can upregulate autoimmunity in murine systemic lupus erythematosus. J Exp Med. 1995;181(6):2017-27.		
	59.	SUGITA, et al. T lymphocyte recognition of human group 1 CD1 molecules: implications for innate and acquired immunity. Semin Immunol. 2000 Dec;12(6):511-6.		
	60.	TRAUTMANN, et al. New insights into the role of T cells in atopic dermatitis and allergic contact dermatitis. Trends Immunol. 2001; 22(10): 530-2.		
	61.	VAN DER VLIET, H.J.J. et al. 1999. Effects of $\alpha$ -galactosylceramide (KRN7000), interleukin-12 and interleukin-7 on phenotype and cytokine profile of human V $\alpha$ 24+ V $\beta$ 11+ T cells. Immunology. 98(4): 557-563.		
	62.	VYSE, et al. Backcross analysis of genes linked to autoantibody production in New Zealand White mice. J Immunol. 1996; 157(6):2719-27.		
	63.	WOLLENBERG, et al. Atopic dermatitis: from the genes to skin lesions. Allergy. 2000; 55(3): 205-13.		
/MD/	64.	ZENG, et al. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. Blood. 1997; 90(1):453-63.		

Examiner Signature	/Marianne Dibrino/	Date Considered	01/28/2008
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.